Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements on October 24, 2006, involving the GlaxoSmithKline Employee Trust ("the GSK Trust"):
- Sale of Shares: The GSK Trust sold 2,849 Ordinary Shares on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of GBP14.88 per share.
- Transfers to Share Value Plan: The GSK Trust transferred 9,805 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
- Transfers to Option Plan: The GSK Trust transferred 82,731 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the trust shares similarly to other employees.
Investor Verification Points
- Verify the total volume of shares transferred to employee plans (91,536 shares) versus shares sold (2,849 shares).
- Confirm the transaction price of GBP14.88 per share against market prices on October 24, 2006.
- Review the specific holdings of the three named directors within the GSK Trust to assess potential conflicts of interest or insider trading implications.